

Index

A

- AADAC. *See* Arylacetamide deacetylase
- Acyldepsipeptides (ADEPs), 376
- Adamantyl ureas, 367
- ADEPs. *See* Acyldepsipeptides
- Adherence, antituberculosis therapy, 512, 514, 525–526, 572
- Adrenal tuberculosis, imaging, 493–494
- AIDS. *See* Human immunodeficiency virus
- AKT1, 424
- AKT2, 424
- Alanine racemase, 340
- Alispovir, tuberculosis studies, 47
- Alr, 343
- Alveolar macrophage. *See* Macrophage
- Amino acid transporters, *Mycobacterium tuberculosis*, 27
- Amoxicillin/clavulanic acid
 - adverse events, 588
 - dosing, 588
 - mechanism of action, 588
 - monitoring, 588
- AMPK, autophagy role, 55
- AMPs. *See* Antimicrobial peptides
- Anakacin
 - dosing, 585
 - mechanism of action, 585
 - adverse events, 509, 513, 585
 - monitoring, 585
- Animal models. *See specific models*
- AnsP1, 320
- Antibodies. *See* B cell
- Antigens, *Mycobacterium tuberculosis*
 - CD8 T cell antigens
 - epitope discovery
 - genome-wide studies, 97
 - reverse immunogenetics, 95–96
 - T cell clone studies, 97
 - identification, 95
 - processing and presentation, 94–95
 - classification of protein-based antigens, 91–92
 - diagnostics, 472–473
 - discovery
 - epitopes, 91
 - genome-wide approaches, 92–94
 - protein-based antigens, 90–91
 - disease stage-specific antigens, 92
 - $\gamma\delta$ T cell recognition, 114–115
 - lipid antigens. *See* CD1-restricted T cell
 - MAIT cell, 111–112
 - metabolic state-specific antigens, 92
 - prospects for study, 97–98
 - vaccines. *See* Vaccination
- Antimicrobial peptides (AMPs), *Mycobacterium tuberculosis* defense, 12
- Apoptosis
 - host defense role, 40–41
 - macrophages in granuloma, 149–150
 - manipulation by *Mycobacterium tuberculosis*
 - genes in inhibition, 42
 - overview, 41
 - therapeutic targeting, 46–47
 - mitochondrial outer membrane permeability loss, 37–38
 - pathway classification, 39
- Arabinofuranosyltransferases, discovery, 303–304
- Arabinogalactan
 - biosynthesis
 - arabinan, 302–303
 - arabinan precursors, 301–303
 - arabinofuranosyltransferase discovery, 303–304
 - galactan, 302
 - galactan precursors, 300–301
 - linker unit, 300
 - cell wall overview, 296
 - structural features, 299–300
- Arylacetamide deacetylase (AADAC), 391
- Autophagy
 - defenses of *Mycobacterium tuberculosis*, 59–61
 - genetic predisposition to tuberculosis, 61
 - host-directed therapy discovery, 424–425
 - immune signaling and autophagy as
 - anti-*Mycobacterium tuberculosis* effector, 58
 - induction by nutritional signals, 54–56
 - LC3-associated autophagy, 57–58
 - mechanisms of *Mycobacterium tuberculosis* killing, 58–59
 - overview, 53–54
 - pathway, 54
 - protection against *Mycobacterium tuberculosis*
 - infection, 61
 - inflammation and tuberculosis pathogenesis, 61–63
 - selective autophagy, 56–57

Index

Autophagy (*Continued*)

- TLR4 in *Mycobacterium tuberculosis* clearance, 5
- ubiquitination and autophagic clearance of *Mycobacterium tuberculosis*, 9, 11–12

B

Bacillus Calmette–Guérin (BCG)

- antibodies in efficacy, 135–136
- CD1-restricted T cell response, 109–110
- CD4 T cell pathogenic responses, 77–78
- historical perspective, 164–165
- immune response
 - effector cells, 165–166
 - long-lived memory, 166–167
- impact on tuberculosis, 163–164, 456
- Listeriolysin O expression, 46–47

B cell

- antibodies
 - infection state studies in *Mycobacterium tuberculosis*, 133–135
 - passive transfer studies, 123, 128
 - protection mechanisms against *Mycobacterium tuberculosis*, 131–133
 - protective antibody characteristics, 133
 - susceptibility to *Mycobacterium tuberculosis* infection studies, 128–129
 - vaccine efficacy studies, 135–136
- antigen presentation, 130
- functional overview, 121–122
- immune cell interactions in *Mycobacterium tuberculosis* infection, 129–131
- Mycobacterium tuberculosis* humoral immune response
 - complexity, 122–123
 - evidence in protection against tuberculosis, 123–129
 - prospects for study, 136

BCG. *See* Bacillus Calmette–Guérin

BDQ. *See* Bedaquiline

Bedaquiline (BDQ)

- adverse events, 513, 587
- dosing, 587
- drug-resistant tuberculosis treatment, 511, 591
- formulation, 367
- historical perspective, 356–357
- mechanism of action, 587
- monitoring, 587
- resistance, 338, 357

BfrA, 373

BfrB, 373

BioA, 340, 343

Biomarkers, tuberculosis

- genetic biosignatures, 185–187
- high-throughput platforms, 183–184
- immunologic biomarkers

- disease-specific biomarker signatures, 204–205
 - early disease biomarker development
 - importance, 199–200
 - overview, 197–198
 - prospects for study, 205–206
 - protein biomarker discovery
 - antigen-stimulated peripheral blood, 200–201
 - immune cell phenotyping, 201
 - serum and plasma, 201
 - untargeted approaches, 201–202
 - transcriptomics approach to discovery
 - focused transcriptomics, 203–204
 - meta-like analysis, 202–203
 - microRNA profiling, 203
 - machine learning model
 - algorithms, 188, 190
 - overview, 188
 - performance of biosignatures, 190–192
 - metabolic profiling, 187
 - predictive biosignatures, 192–194
 - sensitivity and specificity, 184–185
 - transcriptomics studies in whole blood, 189–190
 - variability, 199
- Biotin ligase (BirA), 342
- BirA. *See* Biotin ligase
- BM212, 286

C

Carbon monoxide (CO), bactericidal activity, 6

Cardiac tuberculosis, 497

CD1-restricted T cell

CD1 molecules

- expression modulation and evasion by *Mycobacterium tuberculosis*, 111
- mycobacterial lipid antigen presentation, 107–109
- structure, expression, and intracellular expression, 106–107

function in mycobacterial infection, 109–111

guinea pig model, 221

lipid-specific cell function, 106

CD4 T cell

antigens. *See also* Antigens, *Mycobacterium tuberculosis*

epitope discovery

- genome-wide studies, 97
- reverse immunogenetics, 95–96
- T-cell clone studies, 97

identification, 95

processing and presentation, 94–95

B-cell interactions, 130–131 cell

granuloma necrosis studies, 153–154

host defense against tuberculosis, 94

- mouse *Mycobacterium tuberculosis* infection
 - response, 214–215
 - pathogenic responses during *Mycobacterium tuberculosis* infection
 - human immunodeficiency virus coinfection studies, 78–79
 - immune reconstitution inflammatory syndrome, 78–79
 - negative regulation of responses, 79–81
 - vaccination studies, 77–78
 - phenotyping, 201
 - priming
 - delay following *Mycobacterium tuberculosis* exposure, 74
 - dendritic cell role, 74–75
 - monocytes, 75
 - protective responses during *Mycobacterium tuberculosis* infection
 - cell migration, 76–77
 - interferon- γ -independent mechanisms, 75–76
 - overview, 90
 - Th1 immunity in host resistance, 75
 - tuberculosis infection response, 519–520
 - vaccine immune response, 165–167
- CD8 T cell
- antigens
 - epitope discovery
 - genome-wide studies, 97
 - reverse immunogenetics, 95–96
 - T-cell clone studies, 97
 - identification, 95
 - processing and presentation, 94–95
 - phenotyping, 201
 - vaccine immune response, 165–166
- Cell envelope
- architecture in *Mycobacterium tuberculosis*, 274–275
 - extractable lipids
 - glycerophospholipids, 275, 277, 280–281
 - trehalose esters, 280
 - lipid biosynthesis
 - inhibitors and drug discovery, 279–279, 283–287
 - regulation, 281
 - mycolic acids
 - structures, 276
 - therapeutic targeting, 274–275, 278–279, 285–286
 - overview, 273–274
 - pathogenesis role of *Mycobacterium tuberculosis* lipids, 282–283
 - prospects for study, 287
 - triglycerides, 281, 287
- Cell wall. *See* Arabinogalactan; Peptidoglycan
- Central nervous system tuberculosis
 - clinical presentation and diagnosis in adults, 546–548
 - drug-resistant tuberculosis, 595
 - imaging
 - meningeal tuberculosis, 488–489
 - overview, 485–487
 - parenchymal tuberculosis, 487–488
 - spinal tuberculosis, 489–490
- Cervical lymphadenitis, children, 565, 567
- Childhood tuberculosis
 - adult-type disease, 565–566
 - cervical lymphadenitis, 565, 567
 - clinical syndromes, 561–562, 566
 - diagnosis
 - clinical evaluation, 568
 - imaging, 568–569
 - laboratory studies, 569–570
 - drug-resistant tuberculosis management, 595
 - epidemiology, 455, 557–559
 - immune reconstitution inflammatory syndrome, 567–568, 572
 - latent tuberculosis infection management, 526
 - lymph node tuberculosis, 560, 563–564
 - management, 570–572
 - miliary tuberculosis, 560
 - natural history, 559–560
 - perinatal tuberculosis, 567
 - pleural or percardial effusion, 563, 565
 - prevention, 572, 574
 - pulmonary tuberculosis, 560
 - tuberculous meningitis, 566–567
- Cholesterol, therapeutic targeting of metabolism, 374–375
- Chromosome segregation, imaging in *Mycobacterium tuberculosis*, 264–267
- Chronic obstructive pulmonary disease (COPD), tuberculosis comorbidity, 617, 625
- Clarithromycin
 - adverse events, 590
 - dosing, 590
 - mechanism of action, 590
 - monitoring, 590
- ClgR, 375–376
- Clofazimine, 426
 - adverse events, 588
 - dosing, 588
 - mechanism of action, 588
 - monitoring, 588
- ClpC1, 375
- ClpC2, 375
- ClpP, therapeutic targeting, 370, 375–376
- CO. *See* Carbon monoxide
- Comparative genomics, *Mycobacterium tuberculosis* complex variability, 436–439
 - Mycobacterium*-level variability, 439–441
 - overview, 433–434
 - prospects for study, 44
 - sensu stricto variability, 434–436

Index

- Complement, activation in tuberculosis, 186
Computed tomography (CT)
 abdominal tuberculosis, 491–493
 central nervous system tuberculosis, 488–490
 children, 568
 lymph node tuberculosis, 540
 miliary tuberculosis, 548
 musculoskeletal tuberculosis, 496, 543
 neck tuberculosis, 490
 nonhuman primate models, 249–250, 254
 PET–CT scanning of tuberculosis, 497–500
 pulmonary tuberculosis, 482–484
Contact tracing, latent tuberculosis infection
 prevention, 527
Control. *See* Transmission, tuberculosis
COPD. *See* Chronic obstructive pulmonary disease
Copper
 antioxidant enzyme dependence, 25
 Mycobacterium tuberculosis competition for cations,
 13
Corynebacterium glutamicum,
 arabinofuranosyltransferase discovery,
 303–304
Cotrimoxazole, drug-resistant tuberculosis treatment,
 512
COX. *See* Cyclooxygenase
C-reactive protein (CRP), tuberculosis treatment
 response, 202
CRP. *See* C-reactive protein
CT. *See* Computed tomography
CTLA-4, 154
CtpC, 26
CtpV, 13
Cyclooxygenase (COX), therapeutic targeting, 421
Cycloserine
 adverse events, 585–586
 dosing, 585–586
 mechanism of action, 585–586
 monitoring, 585–586
Cytotoxic T cell. *See* CD8 T cell
- D**
- DC. *See* Dendritic cell
Ddl, 340
Ddn, 378
Decaprenyl phosphate, therapeutic targeting, 279, 286
Dectin-1, signaling in response to *Mycobacterium tuberculosis*, 2
Defensins, *Mycobacterium tuberculosis* defense, 12
Delamanid, drug-resistant tuberculosis treatment,
 511–512
Dendritic cell (DC)
 apoptotic macrophage antigen presentation, 41
 CD4 T-cell priming in *Mycobacterium tuberculosis*
 infection, 74–75
 conventional cells, 71–72
 inflammatory cells, 72–73
 receptor cross talk in differentiation and activation,
 30–32
 subset diversity identification in vivo, 71
Desipramine, tuberculosis studies, 47
DHFR. *See* Dihydrofolate reductase
Diabetes, tuberculosis comorbidity, 617–621, 625
Diagnosis, tuberculosis
 childhood tuberculosis
 clinical evaluation, 568
 imaging, 568–569
 laboratory studies, 569–570
 drug-resistant tuberculosis, 582–583
 latent tuberculosis infection
 cost-effectiveness, 524
 interferon- γ release assay, 522–525
 sensitivity, 523
 specificity, 523–524
 tuberculin skin test, 522, 525
 drug therapy
 adverse events, 526
 clinical trials, 524–526
 special populations, 526
 management
 anti-tumor necrosis factor patients, 527–528
 human immunodeficiency virus patients, 527
 migrants, 528
 newly infected individuals, 526–527
 prospects for study, 528
 biomarkers. *See* Biomarkers, tuberculosis
 needs, 463–464
 microscopy, 464–465, 467
 World Health Organization policy statements, 460
 capacity by global region, 466
 culture-based diagnosis drug susceptibility testing,
 467–467
 nucleic acid amplification tests
 automation, 472
 commercial tests, 469
 line probe assay, 470
 loop-mediated isothermal amplification, 472
 principles, 468
 Xpert MTB/RIF assay, 470–472
 antigen detection, 472–473
 serological assays, 473–474
 interferon- γ release assays, 464
 volatile organic compound detection, 464
 ideal test properties, 474–475
 evaluation of new tests, 475–476
 prospects for study, 476–477
Dihydrofolate reductase (DHFR), 340, 343
Dihydrolipoamide acyltransferase (DlaT), therapeutic
 targeting, 377
Diphtheria toxin receptor (DTR), mouse tuberculosis
 model expression, 212–213

- Disseminated disease. *See* Miliary tuberculosis
- DlaT. *See* Dihydrolipoamide acyltransferase
- DosR, 409
- Double-stranded RNA-dependent protein kinase (PKR), host-directed therapy discovery, 425
- DprE1, 301–302, 367–368
- DprE2, 301
- Drug resistance. *See also specific drugs*
- causes, 581
 - classification, 580
 - community-based care for multidrug-resistant tuberculosis, 596–597
 - diagnosis, 582–583
 - epidemiology, 454–455, 579–581
 - live cell time-lapse imaging of drug-resistant strains, 264
 - resistance mutation selection and identification in drug mechanism of action studies, 338–339
 - risk factors, 583
 - treatment
 - World Health Organization guidelines, 509, 511–512, 583
 - drug dosing and side effects, 584–590
 - regimen design, 591–502
 - duration and monitoring, 592–593
 - side effect management, 593–594
 - surgical resection, 594–595
 - extrapulmonary tuberculosis, 595
 - children, 595
 - pregnancy, 595–596
 - human immunodeficiency virus coinfection, 596
- DTR. *See* Diphtheria toxin receptor
- E**
- Eis
- apoptosis manipulation by *Mycobacterium tuberculosis*, 42
 - autophagy defense, 59
- EMB. *See* Ethambutol
- Enoyl reductase, 354
- Epidemiology, tuberculosis
- case notifications and treatment success, 451–453
 - childhood tuberculosis, 455, 557–559
 - control goals, 446, 455–457
 - global monitoring of disease burden, 446, 448–449
 - human immunodeficiency virus coinfection, 453–454
 - incidence, 449–451
 - molecular. *See* Molecular epidemiology
 - mortality, 448–449, 451
 - multidrug-resistant tuberculosis, 454–455
 - overview, 445–446
 - prevalence, 451
 - prospects for study, 457–458
 - Stop TB Strategy, 447–448
- Ergosterol peroxide, 371
- ESAT-6, 59, 91, 95, 174–175
- ESX-1, 11, 40, 43, 46, 59, 146–148, 152–153, 237, 438, 441
- ESX-3, 26–27
- Ethambutol (EMB)
- adverse events, 509, 584
 - childhood tuberculosis, 573
 - dosing, 584
 - historical perspective, 355–356
 - mechanism of action, 283, 302–303, 584
 - monitoring, 584
 - resistance, 303, 355
 - World Health Organization tuberculosis treatment guidelines, 508–510
- Ethionamide
- adverse events, 586
 - dosing, 586
 - mechanism of action, 273–274, 283–284, 586
 - monitoring, 586
- Evolution. *See* Molecular epidemiology
- Extensively drug-resistant tuberculosis. *See* Drug resistance
- F**
- fabF*, 344
- FadD32, 285–286
- FAS-I. *See* Fatty acid synthase-I
- FAS-II. *See* Fatty acid synthase-II
- FAST, tuberculosis control, 635–646
- Fatty acid synthase-I (FAS-I), 283
- Fatty acid synthase-II (FAS-II), 285, 353, 371
- FoxP3, CD4 T-cell regulation, 79–80
- G**
- Galactan. *See* Arabinogalactan
- $\gamma\delta$ T cell
- antigen recognition, 114–115
 - functional overview, 114
 - immunotherapy modulation, 426
 - tuberculosis immune response, 111
- GAS pathway, 316
- Gastrointestinal tract tuberculosis, imaging, 493
- Gbp7, 9–10
- Genitourinary tuberculosis
- clinical presentation and diagnosis in adults, 544
 - imaging, 494–495
- Ghon complex, 533, 560
- GlcB, 371
- GlfT1, 302
- GlfT2, 302
- GlgE, 377

Index

- GlmM, 296
GlmS, 296
GlmU, 296–297
Glucose monomycolate (GMM), 107–108
Glycerol monomycolate (GroMM), 107–108
GMM. *See* Glucose monomycolate
Granuloma
 cavitary granulomas as vehicles for tuberculosis
 transmission, 154–155
 CD4 T cell in granuloma necrosis, 153–154
 history of study, 155–156
 infection expansion via RD1/ESX-1 virulence
 locus, 146–148
 initiation
 animal models, 145
 innate immunity, 144
 macrophage studies
 apoptosis, 149–150
 egress of infected macrophages, 151
 foamy macrophages, 152
 initiation role, 144
 necrosis, 151–153
 matrix metalloproteinase-9 in formation, 148–149
 neutrophil function, 150–151
GroMM. *See* Glycerol monomycolate
Guinea pig model
 clinical manifestations, 219–220
 drug development, 224
 granuloma formation, 145
 immune response, 221, 223
 Mycobacterium bovis, 224–225
 natural transmission studies, 225
 overview, 219
 pathology, 221, 224
 prospects, 225
 replication of *Mycobacterium tuberculosis*, 220–221
 susceptibility to tuberculosis, 219
 vaccine studies, 222–225
- ## H
- HAP. *See* Haploinsufficiency profiling
Haploinsufficiency profiling (HAP), 341
HBHA. *See* Heparin-binding hemagglutinin
Helminth infection, tuberculosis comorbidity,
 623–524, 626
Heparin-binding hemagglutinin (HBHA), 46
HGT. *See* Horizontal gene transfer
HIV. *See* Human immunodeficiency virus
Homozygous deletion profiling (HOP), 341
HOP. *See* Homozygous deletion profiling
Horizontal gene transfer (HGT), 440
Host-directed therapy
 advantages, 418
 anti-inflammatory therapies
 eicosanoid modulation, 419–421
 nonsteroidal anti-inflammatory drugs,
 421–422
 overview, 418–419
 phosphodiesterase inhibitors, 419
 dual host-targeting and antimicrobial functions,
 426–427
 identification of novel therapies
 autophagy, 424–425
 cell culture–based screens, 424
 double-stranded RNA-dependent protein
 kinase, 425
 imatinib, 422
 immunopathology models
 matrix metalloproteinases, 425–426
 neutrophils, 425
 overview, 425
 immunotherapy, 426
 lipid metabolism targeting, 422–423
 prospects, 427
 vitamin D, 423–424
Human immunodeficiency virus (HIV)
 B-cell response, 131
 epidemiology, 599–600
 immune reconstitution inflammatory syndrome,
 78–79, 418, 567–568, 572, 603–606
 tuberculosis coinfection
 adverse events of antiretrovirals with
 antituberculosis drugs, 513, 605–607
 CD4 T-cell pathogenic response, 78–79
 children, 557–558, 572, 574
 clinical presentation and diagnosis in adults,
 535–536
 drug regimens, 605
 drug-resistant tuberculosis management, 596
 drug-resistant tuberculosis treatment, 512
 epidemiology, 453–454, 600–601
 imaging of tuberculosis, 485
 latent tuberculosis infection, 527
 Mycobacterium tuberculosis effects on
 progression, 31, 604–605
 nonhuman primate models, 251
 overview, 619, 621–622
 prevention, 607–608
 susceptibility, 601–603
Humoral immunity. *See* B cell
- ## I
- ICL. *See* Isocitrate lyase
IdeR, 373
IDO, 15
IFN- α . *See* Interferon- α
IFN- β . *See* Interferon- β
IFN- γ . *See* Interferon- γ
IGRA. *See* Interferon- γ release assay
IL-1. *See* Interleukin-1

- IL-2. *See* Interleukin-2
IL-10. *See* Interleukin-10
IL-12. *See* Interleukin-12
Imatinib
 host-directed therapy, 422
 latent tuberculosis infection in patients, 527–528
Imipenem/cilastatin
 adverse events, 588–589
 dosing, 588–589
 mechanism of action, 588–589
 monitoring, 588–589
Immune reconstitution inflammatory syndrome (IRIS),
 78–79, 418, 567–568, 572, 603–606
Immunotherapy, host-directed therapy, 426
Indole-2-carboxamides, 367
Infection, tuberculosis
 determinants, 519
 risk factors, 521
Influenza, tuberculosis comorbidity, 623
INH. *See* Isoniazid
InhA, 339–340, 371
Interferon- α (IFN- α), signaling in tuberculosis,
 202–203
Interferon- β (IFN- β), signaling in tuberculosis,
 202–203
Interferon- γ (IFN- γ)
 autophagy defense by *Mycobacterium tuberculosis*, 60
 IDO induction, 15
 immunotherapy, 426
 receptor
 mutations and susceptibility to mycobacterial
 diseases, 199
 signaling in response to *Mycobacterium
 tuberculosis*, 2–4
Interferon- γ release assay (IGRA)
 children, 568
 latent tuberculosis infection, 522–525
 overview, 474
Interleukin-1 (IL-1)
 autophagy protection against excessive
 inflammation, 61–62
 receptor signaling in response to *Mycobacterium
 tuberculosis*, 4–5
Interleukin-2 (IL-2), immunotherapy, 426
Interleukin-10 (IL-10), CD4 T cell regulation, 79
Interleukin-12 (IL-12), mutations and susceptibility
 to mycobacterial diseases, 199
IRF3, 61
Irg1, 13–15
Irg1, 318
IRIS. *See* Immune reconstitution inflammatory
 syndrome
Iron
 acquisition by *Mycobacterium tuberculosis*
 overview, 372–373
 therapeutic targeting, 373–374
 Mycobacterium tuberculosis competition for cations,
 12–13, 26–27
 storage by *Mycobacterium tuberculosis*, 373
IrtA, 372
IrtAB, 26
IrtB, 372
IS6110, genotyping, 401–404, 406
Isocitrate lyase (ICL), *Mycobacterium tuberculosis*,
 13–14, 27, 344, 376–377
Isoniazid (INH)
 adverse events, 509, 513, 526, 584
 autophagy role against *Mycobacterium tuberculosis*,
 59
 childhood tuberculosis, 573
 dosing, 584
 high-dose, 589
 historical perspective, 352–354
 latent tuberculosis infection management, 525
 mechanism of action, 273–274, 283–284, 339–340,
 353, 584
 monitoring, 584
 preventive therapy in HIV infection, 607
 resistance, 354, 399
 World Health Organization tuberculosis treatment
 guidelines, 508–510
- J**
JNK, 42, 59
- K**
KasA, 339–340
KasB, 340
KatG, 26, 37, 353–354, 410
KLRG1, 80, 214
KshAB, 374
- L**
LAMP. *See* Loop-mediated isothermal amplification
LAN. *See* Lipoarabinomannan
Lariat A, 371
Lasomycin, 376
Latent tuberculosis infection (LTBI)
 antigens, 92–94, 97
 biosignatures, 185–186
 burden importance, 521–522
 diagnosis
 cost-effectiveness, 524
 interferon- γ release assay, 522–523
 sensitivity, 523
 specificity, 523–524
 tuberculin skin test, 522
 health-care worker surveillance, 639–640
 history of study, 518–519

Index

- Latent tuberculosis infection (LTBI) (*Continued*)
immunology and pathogenesis
 host factors, 520–521
 Mycobacterium tuberculosis factors, 520
overview, 517–518
vaccine performance, 166–167, 171, 174
- LC3, 57–58
- LdtMt1, 299
- LdtMt2, 299
- Leopard frog model, granuloma formation, 145
- LepB, 344
- Leprosy
 clinical variability, 188
 clofazimine therapy, 426
- Leukotrienes
 Mycobacterium tuberculosis manipulation of
 programmed necrosis, 44
 programmed necrosis role, 43–44
 therapeutic modulation, 419–420
- Levofloxacin
 adverse events, 585
 dosing, 585
 mechanism of action, 585
 monitoring, 585
- Line probe assay (LPA), 470
- Linezolid
 adverse events, 513, 587–588
 dosing, 587–588
 drug-resistant tuberculosis treatment, 512
 mechanism of action, 587–588
 monitoring, 587–588
- Lipid II, 298
- Lipid antigens. *See* CD1-restricted T cell; Cell envelope
- Lipoamide dehydrogenase (Lpd), therapeutic targeting, 377
- Lipoarabinomannan (LAM), 107–108, 472–473, 476
- Lipomannan (LM), 107–108, 275, 277, 280, 283, 287
- Lipooligosaccharides (LOS), 280
- Listeriolysin O (LLO), *Bacillus Calmette–Guérin*
 expression, 46–47
- Live cell time-lapse imaging
 asymmetric growth
 antibiotic susceptibility and persistence, 261, 263
 drug-resistant strains, 264
 polar growth, 261
 septum positioning, 263–264
 summary of studies, 262
 chromosome segregation, 264–267
 overview, 260–261
 sporulation studies, 267–268
- Liver, tuberculosis imaging, 493
- LLO. *See* Listeriolysin O
- LM. *See* Lipomannan
- Loop-mediated isothermal amplification (LAMP), 472
- LOS. *See* Lipooligosaccharides
- LPA. *See* Line probe assay
- Lpd. *See* Lipoamide dehydrogenase
- LpdC, 25
- LprG, 441
- LRSAM1, 57
- LTBI. *See* Latent tuberculosis infection
- Lymph node tuberculosis
 abdominal tuberculosis, 492
 children, 560, 563–565, 567
 clinical presentation and diagnosis in adults
 extrathoracic lymph nodes, 539
 intrathoracic lymph nodes, 538–539
 drug-resistant tuberculosis, 595
- LysA, 344
- Lysosome, cell-autonomous defense against
 Mycobacterium tuberculosis
 GTPases, 9–10
 overview, 8–9
 ubiquitination and autophagic clearance, 8, 11–12
- ## M
- MAC12343, 340
- Macaque. *See* Nonhuman primate models
- Machine learning. *See* Biomarkers, tuberculosis
- Macrophage
 alveolar macrophages in *Mycobacterium tuberculosis*
 infection establishment
 early infection, 70
 overview, 69–70
 spread to other myeloid cells, 70–71
 apoptotic macrophage antigen presentation, 41
 granuloma
 apoptosis, 149–150
 egress of infected macrophages, 151
 foamy macrophages, 152
 initiation role, 144
 necrosis, 151–153
 inflammatory cells, 72
 polarization, 27–30
 subset diversity identification in vivo, 71
- Magnesium, *Mycobacterium tuberculosis* competition
 for cations, 13
- Magnetic resonance imaging (MRI)
 abdominal tuberculosis, 493–494
 central nervous system tuberculosis, 485–490, 547
 children, 568
 musculoskeletal tuberculosis, 496–497
 nonhuman primate models, 249
- MAIT cell
 antigens, 111–112
 effector functions, 113–114
 microbial metabolites as antigens, 319
 MR1-restricted cell role in mycobacterial infection, 112–113
- Malaria, tuberculosis comorbidity, 622–623
- Malnutrition, tuberculosis comorbidity, 619

- ManLM. *See* Mannose-capped lipoarabinomannan
- Mannose-capped lipoarabinomannan (ManLM), 275, 277, 280, 282–283, 287
- Marmoset. *See* Nonhuman primate models
- Matrix metalloproteinases (MMPs)
- immunopathology models, 425–426
 - MMP-1, granuloma cavitation role, 155
 - MMP-9, granuloma formation role, 148–149
- Mce4, 375
- MctB, 13, 26
- Mechanism-based drug design, 371–372
- Menaquinones, therapeutic targeting, 279, 286–287, 378
- Mendelian susceptibility to mycobacterial diseases (MSMD), 198–199
- Meningitis. *See* Central nervous system tuberculosis; Tuberculous meningitis
- Meropenem
- adverse events, 589
 - dosing, 589
 - drug-resistant tuberculosis treatment with clavulanate, 512
 - mechanism of action, 589
 - monitoring, 589
- Metabolism, *Mycobacterium tuberculosis*
- auxotrophs as bioprobes of host microenvironments, 319–320
 - carbon and amino acid metabolism by *Mycobacterium tuberculosis* and nutritional immunity, 13–15, 26–27
 - carbon metabolism, 316–317, 376–377
 - cholesterol, 374–375
 - drug discovery
 - efficacy impact of metabolism, 323
 - metabolic response to drug treatment, 324
 - therapeutic targeting, 322–323
 - growth absence, 317–318
 - host immune response influences, 318–319
 - iron acquisition. *See* Iron
 - lipid metabolism and host-directed therapy, 422–423
 - metabolic capacity, 315–316
 - metabolomic studies in vivo, 320–321
 - nutrient sources in host, 315
 - overview, 311–312, 314
 - prospects for study, 324–326
 - resources, 313
- MGIT. *See* Mycobacteria Growth Indicator Tube
- MgtC, 25
- MicroRNA
- neutrophil regulation, 425
 - profiling for biomarker discovery, 203
- Miliary tuberculosis
- children, 560
 - clinical presentation and diagnosis in adults, 548–549
- Mincle, signaling in response to *Mycobacterium tuberculosis*, 2
- MIRU–VNTR, molecular epidemiology studies, 402–404, 406, 408
- MmpL proteins, therapeutic targeting, 367–368, 373–374
- MMPs. *See* Matrix metalloproteinases
- Molecular epidemiology
- classical genotyping, 401–403
 - genomic diversity of *Mycobacterium tuberculosis*
 - global diversity and evolution, 405–409
 - pathobiological consequences, 409–410
 - whole-genome sequencing, 403–405
- Monocyte
- CD4 T-cell priming in *Mycobacterium tuberculosis* infection, 75
 - inflammatory cells, 72
- Mononuclear phagocyte system (MPS)
- dendritic cell differentiation and activation, 30–32
 - intracellular killing resistance mechanisms, 25–26
 - macrophage polarization, 27–30
 - nutrient acquisition by *Mycobacterium tuberculosis*, 26–27
 - overview, 23–24
 - phagosome maturation arrest by *Mycobacterium tuberculosis*, 24–25
- Mortality, tuberculosis, 448–449, 451
- Mouse models
- applications in drug and vaccine development, 215–216
 - genetic manipulation, 212
 - granuloma formation, 145
 - Mycobacterium canettii*, 409
 - overview, 211–212
 - pathological consequences of *Mycobacterium tuberculosis* infection, 214–215
 - T-cell response in *Mycobacterium tuberculosis* infection, 213–214
 - targeted cellular approaches, 212–213
- Moxifloxacin
- adverse events, 585
 - dosing, 585
 - mechanism of action, 585
 - monitoring, 585
- MPS. *See* Mononuclear phagocyte system
- MRI, 111–114
- MRI. *See* Magnetic resonance imaging
- MSMD. *See* Mendelian susceptibility to mycobacterial diseases
- MtrA, 266
- MtrB, 266
- Multidrug-resistant tuberculosis. *See* Drug resistance
- MurB, 297
- MurC, 297
- MurD, 297
- MurE, 297

Index

- MurF, 297
MurG, 298
Musculoskeletal tuberculosis
 clinical presentation and diagnosis in adults,
 542–544
 drug-resistant tuberculosis, 595
 imaging, 495–497
Mycobacteria Growth Indicator Tube (MGIT), 394
Mycobacterium avium subsp. *paratuberculosis* (MAP),
 sporulation, 268
Mycobacterium bovis
 guinea pig model, 224–225
 host range, 407
Mycobacterium indicus pranii, killed vaccine, 171
Mycobacterium kansasii, comparative genomics, 440
Mycobacterium marinum. *See also* Zebrafish model
 comparative genomics, 439–440
 general properties, 230, 233
 sporulation studies, 267–268
Mycobacterium smegmatis, arabinofuranosyltransferase
 discovery, 303–304
Mycolic acids
 antigens, 108–109
 structures, 276
 therapeutic targeting, 274–275, 278–279,
 285–286
MyD88, 58, 144
- N**
- NAAT. *See* Nucleic acid amplification test
NADH dehydrogenase (Ndh), therapeutic targeting,
 377–378
NADPH oxidase
 autophagy role, 59
 mutations and *Mycobacterium tuberculosis*
 susceptibility, 6–7
NasE, 343
Natural products, tuberculosis drug lead generation,
 370–371
Ndh. *See* NADH dehydrogenases
NDH-1, apoptosis manipulation by *Mycobacterium*
 tuberculosis, 42
NDP52, 58
Neck tuberculosis, imaging, 490
Necrosis
 Mycobacterium tuberculosis manipulation
 of programmed necrosis
 genes, 46
 NLRP, 43–44, 46
 prostaglandins and leukotrienes, 44
 therapeutic targeting, 46–47
 overview of programmed necrosis regulation, 38,
 42–43
NEMO, mutations and susceptibility to mycobacterial
 diseases, 199
- Neutrophil
 granuloma function, 150–151
 immunopathology models, 425
 Mycobacterium tuberculosis response, 73–74
NITD-304, 366
NITD-349, 366
NLR. *See* Nod-like receptor
NLRP, *Mycobacterium tuberculosis* manipulation
 of programmed necrosis, 43–44, 46
Nod-like receptor (NLR), signaling in response to
 Mycobacterium tuberculosis, 5
Nonhuman primate models
 advantages, 243–244
 drug and vaccine studies, 251–253
 granuloma formation, 145
 historical perspective, 244
 human immunodeficiency virus–tuberculosis
 coinfection, 251
 imaging studies, 249, 254
 inoculum strain, dose, and route, 247–249
 latent and reactivating disease studies, 250–251
 pathogenesis studies, 250
 primate species comparison, 244–247
 prospects, 253, 255
NRAMP1, 26
Nucleic acid amplification test (NAAT)
 automation, 472
 commercial tests, 469
 line probe assay, 470
 loop-mediated isothermal amplification, 472
 principles, 468
 Xpert MTB/RIF assay, 470–472
Nutrition. *See also specific nutrients*
 autophagy induction by nutritional signals, 54–56
 malnutrition and tuberculosis comorbidity, 619
 Mycobacterium tuberculosis competition for cations,
 12–13
- O**
- Ocular tuberculosis, 497–498, 548
Organ transplant patients, latent tuberculosis infection
 management, 528
- P**
- PA-824, drug-resistant tuberculosis treatment, 512
PanC, 344
Pantothenate synthetase (Pts), 372
ParA, 264–265
Para-aminosalicylic acid (PAS)
 adverse events, 586
 dosing, 586
 historical perspective, 351, 506
 mechanism of action, 358, 586
 metabolic response to drug treatment, 324

- monitoring, 586
 - ParB, 264–265
 - PARKIN, autophagic clearance of *Mycobacterium tuberculosis*, 12
 - PARP. *See* Poly(ADP-ribose) polymerase
 - PAS. *See* Para-aminosalicylic acid
 - PD-1, 80–81, 154, 214
 - PDE. *See* Phosphodiesterase
 - PDMS. *See* Polydimethylsiloxane
 - PDPs. *See* Product-development partnerships
 - PEPCK. *See* Phosphoenolpyruvate carboxykinase
 - Peptidoglycan (PG)
 - biosynthesis in mycobacteria
 - assembly, 298–299
 - cytoplasmic intermediate metabolism, 296–298
 - cell wall overview, 296
 - structural features, 295–296
 - Pericarditis, tuberculosis
 - adults, 549
 - children, 563, 565
 - Perinatal tuberculosis, 567
 - Peritoneal tuberculosis
 - clinical presentation and diagnosis in adults, 544–545
 - imaging, 492–493
 - PET. *See* Positron emission tomography
 - PG. *See* Peptidoglycan
 - PGE₂. *See* Prostaglandin E₂
 - Phagosome
 - formation in tuberculosis infection, 519
 - maturation arrest by *Mycobacterium tuberculosis*, 24–25
 - Pharmacology
 - general concepts, 388–389
 - pharmacodynamics, 389, 391–394
 - pharmacokinetics, 387, 389–391
 - systems pharmacology, 394
 - PhoP, 441
 - Phosphodiesterase (PDE), inhibitor therapy, 419
 - Phosphoenolpyruvate carboxykinase (PEPCK), therapeutic targeting, 377
 - PID. *See* Primary immune deficiency
 - Pkn kinases
 - cell growth and division regulation, 266
 - therapeutic targeting, 279
 - PknG, 25
 - PKR. *See* Double-stranded RNA-dependent protein kinase
 - Pleural effusion, tuberculosis
 - children, 563–565
 - clinical presentation and diagnosis in adults, 539–542
 - PNTZ169, 238
 - POA. *See* Pyrazinoic acid
 - Poly(ADP-ribose) polymerase (PARP), necrosis regulation, 38
 - Polydimethylsiloxane (PDMS), live cell time-lapse imaging application, 260
 - PONA1, 298
 - PONA2, 298
 - Positron emission tomography (PET)
 - drug imaging, 390
 - nonhuman primate models, 249–250, 254
 - PET–CT scanning of tuberculosis, 497–500
 - PptT, 343
 - Pregnancy, drug-resistant tuberculosis management, 595–596
 - Primary immune deficiency (PID), susceptibility to mycobacterial diseases, 198–199
 - Product-development partnerships (PDPs), 365
 - Prostaglandin E₂ (PGE₂), therapeutic modulation, 420, 422
 - PTGS2, 30
 - PtpA, 25
 - Pts. *See* Pantothenate synthetase
 - Pulmonary tuberculosis
 - children, 560
 - imaging
 - active versus inactive disease, 484–485
 - human immunodeficiency virus patients, 485
 - postprimary tuberculosis, 483–484
 - primary tuberculosis, 482–483
 - clinical presentation and diagnosis in adults
 - postprimary tuberculosis, 534–536
 - primary tuberculosis, 532–534
 - Purinergic receptors, signaling in response to *Mycobacterium tuberculosis*, 5–6
 - Pyrazinamide (PZA)
 - adverse events, 509, 584
 - autophagy role against *Mycobacterium tuberculosis*, 59
 - childhood tuberculosis, 573
 - dosing, 584
 - historical perspective, 354–355, 506
 - mechanism of action, 354–355, 584
 - monitoring, 584
 - World Health Organization tuberculosis treatment guidelines, 508–510
 - Pyrazinoic acid (POA), 355
 - PZA. *See* Pyrazinamide
- ## Q
- QcrB, therapeutic targeting, 366, 369, 378
- ## R
- Rab
 - lysosome delivery of *Mycobacterium tuberculosis*, 9
 - phagosome maturation arrest by *Mycobacterium tuberculosis*, 24
 - Rabbit model, granuloma formation, 145

Index

- RD1, 146–148, 152
- Reactive nitrogen species (RNS)
cell-autonomous defense against *Mycobacterium tuberculosis*, 7–8
therapeutic manipulation, 378–379
- Reactive oxygen species (ROS)
cell-autonomous defense against *Mycobacterium tuberculosis*, 6–7
induction by *Mycobacterium tuberculosis*, 7
therapeutic manipulation, 378–379
- Rifampicin
adverse events, 509, 526, 584
childhood tuberculosis, 573
dosing, 584
historical perspective, 356
latent tuberculosis infection management, 525
mechanism of action, 584
monitoring, 584
pharmacokinetics, 390–391
resistance, 356, 399
resistance, 580
World Health Organization tuberculosis treatment guidelines, 508–510
- RING, 57
- RipA, 266, 298
- RIPK1, necrosis regulation, 38, 45, 53
- RIPK2, 58
- RIPK3, 153
- RNA profiling, drug mechanism of action studies, 337–338
- RNS. *See* Reactive nitrogen species
- RodA, 298
- ROS. *See* Reactive oxygen species
- rpf* genes, 266–267
- RpfB, 298
- rpoA*, 410
- rpoB*, 324, 340, 410
- rpoC*, 410
- RskA, 439
- S**
- SAA. *See* Serum amyloid A
- SapM, 25
- SecA2, 26
- Septum
formation, 299
positioning in *Mycobacterium tuberculosis*, 263–264
- Serum amyloid A (SAA), tuberculosis treatment response, 202
- Silicotuberculosis, 539
- SLCO1B1, 391
- SLR, 56, 48
- SOCS3, 186
- SOD. *See* Superoxide dismutase
- Spinal tuberculosis
clinical presentation and diagnosis in adults, 532–534
imaging, 489–490
- Splenic tuberculosis
clinical presentation and diagnosis in adults, 545
imaging, 493
- Sporulation, mycobacteria, 267–268
- STAT1
mutations and susceptibility to mycobacterial diseases, 199
signaling in response to *Mycobacterium tuberculosis*, 2–3
- STING, 11, 424
- Stop TB Strategy, 447–448
- Streptomycin, historical perspective, 506
- Structure-based drug design, 371–372
- Superoxide dismutase (SOD), *Mycobacterium tuberculosis* production, 25–26, 40–42
- Surgical resection, drug-resistant tuberculosis, 594–595
- Syt-7, 44
- T**
- T cell. *See* CD1-restricted T cell; CD4 T cell; CD8 T cell; $\gamma\delta$ T cell; MAIT cell
- Tgs1, 323
- Thiacetazone
adverse events, 590
dosing, 590
mechanism of action, 590
monitoring, 590
- Thiolactomycin (TLM), 340
- Thuggacin A, 370–371
- Time-lapse imaging. *See* Live cell time-lapse imaging
- TLM. *see* Thiolactomycin
- TLR. *See* Toll-like receptor
- TMC-207, 366
- TNF- α . *See* Tumor necrosis factor- α
- Toll-like receptor (TLR)
autophagy role, 5
dendritic cell differentiation and activation through receptor cross talk, 31
necrosis regulation, 38
signaling in response to *Mycobacterium tuberculosis*, 2–5
- Transmission, tuberculosis
cavitary granulomas as vehicles, 154–155
childhood tuberculosis, 559
guinea pig natural transmission studies, 225
- Transmission, tuberculosis
airborne *Mycobacterium tuberculosis*, 632
control
ambulatory versus inpatient treatment, 636–637
environmental control

- crowding, building design, and usage, 637
- upper room ultraviolet germicidal irradiation, 638–639
- ventilation, 637–638
- FAST, 635–646
- goals, 446, 455–457
- health-care worker surveillance, 639–640
- interventions, 634–635
- respirators, 539
- treatment impact, 635
- dose and risk of infection, 633–634
- mechanisms, 631–632
- source factors, 634
- Transposon site hybridization (TraSH), 342–343
- TraSH. *See* Transposon site hybridization
- TREM1, 185, 203
- Trichoderin A, 371
- TRIF, autophagy role, 5
- TrpE, 319
- TST. *See* Tuberculin skin test
- Tuberculin skin test (TST), latent tuberculosis infection, 522, 525
- Tuberculous meningitis
 - children, 566–567
 - drug-resistant tuberculosis, 595
 - imaging, 488–489
- Tumor necrosis factor- α (TNF- α)
 - apoptosis manipulation by *Mycobacterium tuberculosis*, 41
 - granuloma macrophage necrosis studies, 152–153
 - latent tuberculosis infection in anti-tumor necrosis factor patients, 527–528
 - receptor signaling in response to *Mycobacterium tuberculosis*, 2, 4
- U**
- Ubiquitination, autophagic clearance of *Mycobacterium tuberculosis*, 9, 11–12
- ULK1, 55–56, 58, 60, 63
- Ultraviolet germicidal irradiation (UVGI), tuberculosis prevention, 638–639
- UVGI. *See* Ultraviolet germicidal irradiation
- V**
- Vaccination. *See also* Bacillus Calmette–Guérin
 - administration windows, 167, 171
 - antibodies in efficacy, 135–136
 - clinical trials, 168–169
 - disease stage targeting, 170
 - guinea pig model, 222–225
 - human immunodeficiency virus–tuberculosis coinfection prevention, 607–608
 - latent tuberculosis, 173–175
 - live vaccines, 171
 - nonhuman primate models, 251–253
 - prospects, 175–176
 - subunit vaccines
 - adjuvanted vaccines, 172–173
 - viral vectors, 171–172
- VDR. *See* Vitamin D receptor
- Vitamin D
 - autophagy defense by *Mycobacterium tuberculosis*, 60–61
 - host-directed therapy, 423–424
- Vitamin D receptor (VDR), signaling in response to *Mycobacterium tuberculosis*, 5
- VOCs. *See* Volatile organic compounds
- Volatile organic compounds (VOCs), diagnostics, 464
- W**
- WCS. *See* Whole-cell screening
- Whole-cell screening (WCS)
 - drug discovery and mechanism of action, 335–336, 341–342
 - prospects, 344–345
 - target-directed, 344
- Whole-genome sequencing, molecular epidemiology studies, 403–405
- X**
- Xpert MTB/RIF assay, 470–472, 569
- Z**
- Zebrafish model
 - advantages as model system, 230, 238
 - complementary features of embryo and adult systems, 235, 237
 - drug discovery, 237–238
 - genetic susceptibility, 235
 - granuloma
 - dynamics, 235
 - formation, 145, 232, 236
 - immune system development, 230–231
 - infection routes, 232–233
 - Mycobacterium marinum* properties, 230, 233
 - overview of *Mycobacterium marinum* model, 229–230
 - pathology
 - adults, 233–234
 - embryos, 234
 - prospects for study, 238
 - virulence factors, 237
- Zinc, *Mycobacterium tuberculosis* competition for cations, 13
- Zmp1, 25